TITLE

The reporting of methods for reducing and detecting bias: an example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial

AUTHOR(S)
Piaggio, Gilda; Elbourne, Diana; Schulz, Kenneth F.; Villar, José; Pinol, Alain P. Y.; Gülmezoglu, A. Metin
PUB. DATE
January 2003
SOURCE
BMC Medical Research Methodology;2003, Vol. 3, p19
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The aim of this article is to explore ways in which selection bias and ascertainment bias can be reduced and investigated in trials, by using the example of a drug trial carried out in both developed and developing countries in hospital delivery wards. Methods: We describe an innovative and practical design for the boxes for packing the drugs as a way of increasing the security of allocation concealment and blinding. We also assess ascertainment bias using sensitivity analyses, as some unblinding could have occurred due to a potential side effect of one of the drugs. Results: The sensitivity analyses indicated that the conclusions about the relative effects of the treatments could be maintained even in the unlikely worst-case scenarios. Conclusions: Detailed description of the procedures protecting against common biases and of the assessment of ascertainment bias in this trial should allow readers to confidently appraise and interpret the results obtained. In addition, our experiences will assist others in planning trials in the future.
ACCESSION #
29404657

 

Related Articles

  • Hunt for malaria vaccine raises a storm. Kabukuru, Wanjohi // New African;Oct2011, Issue 510, p22 

    The article discusses the trial stages of a new vaccine called RTS, S for malaria in Kenya. It presents the countries covered with the trials including Mozambique, Ghana and Malawi. According to the World Health Organisation (WHO), over one million people die annually from malaria and added that...

  • The Platform Trial: An Efficient Strategy for Evaluating Multiple Treatments. Berry, Scott M.; Connor, Jason T.; Lewis, Roger J. // JAMA: Journal of the American Medical Association;4/28/2015, Vol. 313 Issue 16, p1619 

    The article discusses the use of the platform trial, a clinical trial strategy designed to efficiently evaluate and determine the best treatment or combination of treatments for a given disease. Topics include the cost savings of a platform trial to financial supporters such as federal,...

  • Drug Trials and Older People. Witham, Miles D. // Drugs & Aging;2011, Vol. 28 Issue 8, p679 

    No abstract available.

  • From the Editor's desk. Tyrer, Peter // British Journal of Psychiatry;Mar2010, Vol. 196 Issue 3, p254 

    An introduction to the journal is presented in which the editor discusses reports published within the issue including the importance of attention to methodology in clinical trials, restriction of publication bias to drug trials, and the mental ill-effects of neglect, abuse, and deprivation.

  • National Pharmaceutical Institute answers allegations.  // Life Science Today;Feb2001, Vol. 2 Issue 1, p7 

    Reports on the Hungarian National Pharmaceutical Institute's denial that dangerous drug experiments are being carried out on unsuspecting patients. Rules concerning clinical trials in Hungary; Reasons that make Europe an easier place to find clinical trial patients.

  • ADVANCE-2: Apixaban had favorable risk-benefit profile compared with enoxaparin.  // Hem/Onc Today;8/10/2009, Vol. 10 Issue 15, p23 

    The article discusses the results of a clinical drug trial which revealed the therapeutic use of apixaban for thromboprophylaxis after total knee replacement.

  • Safe and well tolerated. Fleischmann, Roy; Goodson, Nicola; Elewaut, Dirk // Rheumatology;Nov2011, Vol. 50 Issue 11, p1942 

    The authors reflect on how to determine what medication is safe and well tolerated by a patient with rheumatoid arthritis (RA). They examine the cases in which the patients have comorbidities that complicate the selection of medication or create problem on the use of an effective treatment. They...

  • Research & Markets: Bacteriuria Global Clinical Trials Review, H2 2011.  // Biomedical Market Newsletter;12/28/2011, Vol. 21, p1 

    The article presents information on a report of clinical trials on Bacteriuria, a urinary tract infection. It also mentions the scope of the data provided in the report. The report highlights the key drugs for the treatment of disease. It also mentions that the clinical trails in report were...

  • The potential and limits for clinical trials for early Alzheimer’s disease and some recommendations. SCHNEIDER, L. S. // Journal of Nutrition, Health & Aging;Apr2010, Vol. 14 Issue 4, p295 

    Recommendations for clinical trials methods for ‘pre-dementia,’ ‘prodromal,’ or early Alzheimer’s disease are discussed. Early AD can be considered as subsets of both ‘amnestic MCI’ and ‘probable AD.’ In principle, it can be...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics